DPDavid James Papke

David James Papke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David James Papke has a total of 143 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Emerging and Under-Recognized Fibroblastic Tumors of the Skin and Subcutis: A Review Highlighting New Entities and Diagnostic Pitfalls

    by Elizabeth C Draper, David J Papke

    Tumor types and novel molecular alterations are being described at an accelerating rate, leading to rapid evolution of the classification system. There have been several recent developments in the classification of superficial fibroblastic and myofibroblastic tumor types, and, accordingly, there have been newly discovered pitfalls relevant to dermatopathology. Here, we survey new developments in the diagnosis and molecular pathogenesis of fibroblastic and myofibroblastic neoplasms of the skin and subcutis. Plexiform myofibroblastoma is a benign tumor type with plexiform architecture that can mimic the more aggressive plexiform fibrohistiocytic tumor. PLAG1 -rearranged fibromyxoid tumor is possibly related to lipoblastoma, occurs in superficial sites, and can mimic low-grade fibromyxoid sarcoma and spindle cell rhabdomyosarcoma. Superficial ALK -rearranged myxoid spindle cell neoplasm is a recently described cutaneous tumor type that can be mistaken for dermatofibrosarcoma protuberans (DFSP), and recent evidence suggests it is on a biologic spectrum with epithelioid fibrous histiocytoma. Similarly, plaque-like CD34-positive dermal fibroma and related NTRK - or ALK- rearranged plaque-like dermal neoplasms represent an expanding group of superficially located CD34-positive spindle cell tumors that may mimic DFSP. Nodular necrotizing fibroblastic tumor is a recently described, typically indolent tumor type that often occurs in skin and subcutis, harbors YAP1 :: MAML2 fusions, and closely mimics myxoinflammatory fibroblastic sarcoma. In addition to these new entities, we discuss some likely under-recognized tumor types that present pitfalls, including fibroblastic connective tissue nevus, which can mimic DFSP, and superficial CD34-positive pleomorphic fibroblastic tumor, which can mimic pleomorphic sarcoma. Collectively, these entities necessitate integrated histologic, immunohistochemical, and, sometimes, molecular evaluation to ensure accurate diagnosis and to avoid overtreatment.

  • AHRR fusion-negative tumors diagnosed as angiofibroma of soft tissue are genetically heterogeneous and differ clinicopathologically from AHRR-rearranged tumors

    by Felix Keil, Igor Odintsov, Stephanie Siegmund, Linda Magnusson, Anna H. Bauer, Daniela Hirsch, Matthias Evert, Fredrik Mertens, Jason L. Hornick, Christopher D. M. Fletcher, et al.

  • Ultrasensitive circulating tumor DNA analysis improves detection of molecular residual disease in locally advanced esophageal cancer

    by Justin Rhoades, Anuj Patel, Kan Xiong, Timothy Blewett, Rachel Li, Laurel Walsh, Andjela Crnjac, James H. Ratty, Oliver Limbo, Alison Hannigan, et al.

    Purpose: Circulating tumor DNA (ctDNA) could be a powerful prognostic biomarker for patients with locally advanced esophageal cancer but higher sensitivity is needed. An ultrasensitive test could enable improved treatment decision-making by accurately identifying patients with residual disease. Experimental Design: 331 plasma samples from 36 patients were collected both preoperatively and postoperatively. We applied MAESTRO-Pool (Minor Allele Enriched Sequencing Through Recognition Oligonucleotides) of the Broad Institute and the Oncodetect® V2 test of Exact Sciences, two MAESTRO-based, ultrasensitive, tumor-informed, mutation enrichment sequencing tests, to all samples. Results: With the Oncodetect V2 test, we found 9 of 14 patients (64%) with recurrence and postoperative plasma available tested ctDNA-positive at their first postoperative sample and all 14 patients tested ctDNA-positive for at least one postoperative sample prior to recurrence. ctDNA was detected below the limit of detection for first-generation assays in 59% of all samples in which we detected ctDNA. By tracking a median of 2.1-fold more mutations per patient (up to 5,000 total mutations per patient), the Oncodetect V2 test showed highly concordant results (98.9% positive percent agreement), improved ctDNA detection, and longer lead times to recurrence as compared to MAESTRO-Pool. Conclusion: ctDNA detection after curative-intent therapy for locally advanced esophageal cancer had strong positive and negative predictive values for recurrence. Given the low ctDNA levels observed, and that all patients with recurrence were eventually ctDNA-positive, ctDNA testing in esophageal cancer may benefit from ultrasensitive tests that detect part-per-million levels of ctDNA.

  • Clinicopathologic Study of 39 Mismatch Repair-deficient Sarcomas Demonstrates Recurrent Histologic Patterns and Supports Universal Screening of Pleomorphic Rhabdomyosarcoma, Uterine Leiomyosarcoma, and Undifferentiated and Unclassified Sarcomas

    by Igor Odintsov, Jonathan A. Nowak, Esther Baranov, Thierry Alcindor, Candace L. Haddox, Vinayak Venkataraman, Lynette M. Sholl, Suzanne George, Leona A. Doyle, Mark Redston, et al.

    Mismatch repair-deficient (dMMR) sarcomas are rare and incompletely characterized. Here, we studied 39 sarcomas with high microsatellite instability (MSI-H) and/or biallelic MMR gene inactivation (21 MSH2 , 9 MLH1 , 4 PMS2 , 4 MSH6 , 1 EPCAM ). All tumors evaluated with immunohistochemistry (IHC; n = 36) showed loss of MMR protein expression. Eight sarcomas were index neoplasms among the 15 patients with documented Lynch syndrome. Eighteen of 1531 sarcomas (1.2%) in our sequencing database were dMMR, with enrichment in pleomorphic rhabdomyosarcoma (PRMS; 1/5), uterine leiomyosarcoma (LMS; 7/124; 5.6%), and unclassified/undifferentiated pleomorphic sarcoma (UPS; 6/259; 2.3%). MMR IHC screening of independent cases confirmed MMR deficiency in PRMS (2/20), uterine LMS (2/20), and unclassified/UPS (1/20). Two histologic patterns were identified among unclassified/UPS. Ten tumors, designated “distinctive lobulated inflammatory sarcoma” (DLIS), showed lobular architecture, florid inflammation, and histiocytoid, variably pleomorphic neoplastic cells. All 6 patients with DLIS and follow-up (median: 6.0 y; range: 3 mo to 8.6 y) were alive with no evidence of disease (ANED), and 2 DLIS responded completely to immune checkpoint inhibition. A morphologically different group of 6 unclassified high-grade sarcomas showed sheets of epithelioid-to-rhabdoid cells with eosinophilic cytoplasm; among 5 patients with follow-up (median: 1.1 y; range: 4 mo to 6.9 y), only 1 was ANED. Surprisingly, all 3 PRMS patients with follow-up (median: 5.7 y; range: 4.2 to 8.3 y) were ANED, including 2 with complete responses of metastases to systemic therapy. We conclude that PRMS, uterine LMS, and unclassified/UPS showed sufficiently prevalent MMR deficiency to justify prospective MMR IHC screening for Lynch syndrome and to identify patients who might benefit from immune checkpoint inhibition. Histologic subtyping of unclassified sarcomas predicted prognosis and therapeutic response. We propose universal MMR IHC screening of (1) PRMS, (2) uterine LMS, (3) unclassified/UPS, and (4) any sarcoma in a patient with a personal or family history of Lynch syndrome.


  • FOS and FOSB Immunohistochemistry and Molecular Testing Reveal Novel Patterns in Proliferative Fasciitis and Myositis, FOSB Rearrangement in Proliferative Funiculitis, and FOSL1::RELA Fusion in Pediatric Proliferative Fasciitis

    by Sanhong Yu, Fleur Cordier, Esther Baranov, Igor Odintsov, Linda Magnusson, Joni Van der Meulen, Siebe Loontiens, Liesbeth Ferdinande, Jo Van Dorpe, Felix Haglund de Flon, et al.

    Proliferative fasciitis (PFA) and proliferative myositis (PM) are related benign neoplasms that show large ganglion-like neoplastic cells and harbor recurrent FOS fusions. Proliferative funiculitis (PFU) is a benign mesenchymal lesion of the spermatic cord, with small ganglion-like cells and unknown etiology. Ischemic fasciitis (IFA) is a possibly reactive lesion that shows cytomorphologic overlap with PFA/PM. Here, we assessed FOS and FOSB immunohistochemistry (IHC) in PFA (adult and pediatric), PM, PFU, and IFA. Diffuse nuclear FOS expression was detected in adult PFA (15/26 cases; 58%) and PM (6/10; 60%), while FOSB was consistently negative (19 adult PFA, 5 PM). FOS FISH demonstrated rearrangement in only 4 of 12 tested adult PFA/PM, all of which were FOS-positive by IHC. A FOS fusion ( FOS::TSHZ2 ) was detected in only 1 of 9 adult PFA/PM (11%) tested by RNA sequencing (RNAseq); 5 tumors without detected FOS fusions by RNAseq were FOS-positive by IHC. The pediatric PFA lacked expression of FOS (all 9 tumors) and FOSB (4 tested tumors) by IHC. Compared with FOS-positive PFA/PM, pediatric PFA and adult FOS-negative PFA/PM were more frequently cellular, and pediatric tumors were less infiltrative. DNA sequencing demonstrated FOSL1 :: RELA fusions in 2 of 5 tested pediatric PFAs, both in infants. Six of 18 PFU (33%) expressed FOS and/or FOSB by IHC. FISH demonstrated FOSB rearrangement in 1 of 6 PFU, while all 6 tested PFU were negative for FOS rearrangement. Nine of 20 IFA (45%) expressed FOS and/or FOSB; 2 tested tumors were negative for FOS or FOSB fusions by RNAseq. We conclude that about 60% of adult PFA/PM strongly express FOS, and 5 of these tumors were proven to harbor FOS rearrangements, including a novel FOS :: TSHZ2 fusion. Some PFU and pediatric PFA harbored alterations in related genes FOSB and FOSL1 , respectively. RNAseq and FISH might have imperfect sensitivity for FOS alterations in PFA/PM, likely due to the low relative neoplastic cell content in these tumor types.

  • Open Access

    Ossifying spindled and epithelioid tumour: Expanding the clinical and morphologic spectrum of a recently described entity

    by Rayan M Sibira, Benjamin F Smith, Amy Davis, Jessica L Davis, Nada Mohamed, Riyam Zreik, David J Papke, Michael Michal, Sintawat Wangsiricharoen, Karen J Fritchie

    Background: Ossifying spindled and epithelioid tumour (OSET) is a recently defined soft tissue neoplasm with characteristic features, including a peripheral shell of bone or pseudocapsule, keratin expression, and indolent behaviour. Here, we present five unique cases of OSET with novel clinical and morphologic features. Materials and methods: Cases of OSET were collected. Clinicopathologic and molecular features were documented. Results: Cases of OSET were collected from lesions arising in the extremities of five patients, ranging in age from 8 to 58 years. Histologically, all tumours were well circumscribed and keratin‐positive. Three showed a mixed spindle and epithelioid cell morphology, whereas two were composed predominantly of epithelioid cells. Two cases harboured mitotic rates of ≥5 mitotic figures per 10 high‐power fields and contained necrosis. While peripheral pseudoencapsulation was consistent, two cases contained minimal peripheral ossification (approximately 5%), and two were entirely non‐ossifying. One OSET case showed multifocal disease with synchronous tumours involving the elbow and wrist of the upper extremity; another represented a local recurrence 7 years after resection of the primary tumour; the remaining three patients are disease‐free. Next‐generation sequencing of tumour RNA revealed an SRSF7::NFATC3 fusion in the three cases evaluated. Conclusion: Our cohort expands the clinical and morphologic spectrum of this entity to include tumours with increased mitotic activity and necrosis, as well as highlights the first two examples of non‐ossifying OSET. Moreover, while confirming the overall indolent behaviour of OSET, we described cases that demonstrate primary multifocal disease and local recurrence.

  • Atypical Vulvovaginal Postradiation Vascular Lesion

    by Alexander J. Neil, Yvonne Y. Li, David J. Papke, Christopher D.M. Fletcher

    Cancers of the endometrium, cervix, and anus are frequently treated with radiation therapy (RT), which carries a risk for secondary malignancies. RT causes vaginal atrophy, dryness, and increased mucosal friability, predisposing to ulcers. Here, we describe “atypical vulvovaginal postradiation vascular lesion” (AVPRVL), a benign post-RT vascular lesion that histologically mimics angiosarcoma. Fifteen cases were retrospectively identified in patients aged 44 to 77 years (median: 70 y) who presented 3 to 23 years post-RT (median: 14 y), usually with vaginal bleeding. Histologically, AVPRVL demonstrated papillary endothelial hyperplasia (Masson change), mild-to-moderate nuclear atypia, and direct juxtaposition to squamous epithelium. Atypical vessels were located in fibrin and were not distributed in the native lamina propria. MYC immunohistochemistry demonstrated only scattered, weak expression in 5 tested lesions. Fluorescence in situ hybridization was negative for MYC amplification in 11 tested lesions. Five sequenced lesions lacked recurrent pathogenic alterations or copy number changes. Clinical follow-up was available for 11 patients (73%; median length: 3.3 y; range: 1 to 21.7 y). None developed metastases. Six patients (55%) experienced persistent or recurrent lesions, although sometimes it was not possible to distinguish true recurrence from new lesions developing in the RT field. At the most recent follow-up, 9 patients were alive with no evidence of disease, and 2 were alive with recurrent lesions. Ultimately, most lesions resolved with excision or cautery. Unlike RT-associated angiosarcoma, AVPRVL lacked MYC amplification, showed indolent clinical behavior, and usually resolved with conservative management. Unlike cutaneous atypical postradiation vascular proliferation, AVPRVL did not show vessels distributed within native subepithelial tissue. Instead, it more closely resembled a Masson change with nuclear atypia. We conclude that AVPRVL represents a distinctive, benign, possibly reactive vascular proliferation of the vulvovaginal mucosa occurring years after pelvic RT. The distinction between AVPRVL and angiosarcoma is critical to avoid overtreatment.


  • Open Access

    Supplementary Table from Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer

    by David J. Papke, Neal I. Lindeman, Deborah Schrag, J. Bryan Iorgulescu

    Supplementary Table from Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer

  • Open Access

    Supplementary Table from Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer

    by David J. Papke, Neal I. Lindeman, Deborah Schrag, J. Bryan Iorgulescu

    Supplementary Table from Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer